• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name:  Doxorubicin liposome
Trade Name:  Doxil
Date Designated:  11/04/1998
Orphan Designation:  Treatment of ovarian cancer.
Orphan Designation Status:  Designated/Approved
Marketing Approval Date:  06/28/1999 
Approved Labeled Indication:  Treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinium-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment.
Exclusivity End Date:    06/28/2006 
Exclusivity Protected Indication* :  
Alza Corporation
1550 Plymouth St.
PO Box 7210
Mountain View, California 94039
United States

The sponsor address listed is the last reported by the sponsor to OOPD.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.